<DOC>
	<DOCNO>NCT01213641</DOCNO>
	<brief_summary>The purpose observational study collect additional information regard long-term safety effectiveness Ilaris treatment CAPS patient clinical practice .</brief_summary>
	<brief_title>Clinical Outcomes Safety : A Registry Study Ilaris ( Canakinumab ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Cryopyrin-Associated Periodic Syndromes</mesh_term>
	<criteria>Patients receive Ilaris ( canakinumab ) time enrollment part medical care Local regulation location may exclude patient receive Ilaris nonapproved indication Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Cryopyrin-associated periodic syndrome ( CAPS )</keyword>
	<keyword>CIAS1 protein</keyword>
	<keyword>NLRP3 protein</keyword>
	<keyword>human cryopyrin protein</keyword>
	<keyword>Familial Cold Autoinflammatory Syndrome ( FCAS )</keyword>
	<keyword>Muckle-Wells Syndrome ( MWS )</keyword>
	<keyword>Neonatal Onset Multisystem Inflammatory disease ( NOMID )</keyword>
	<keyword>NALP3</keyword>
	<keyword>canakinumab</keyword>
	<keyword>Interleukin-1 ( IL-1 )</keyword>
</DOC>